Edition:
United Kingdom

Profile: Erytech Pharma SA (ERYP.PA)

ERYP.PA on Paris Stock Exchange

6.61EUR
24 May 2019
Change (% chg)

-- (--)
Prev Close
€6.61
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
36,027
52-wk High
€16.89
52-wk Low
€5.61

Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The Company's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death. The Company's subsidiary is Erytech Pharma, Inc in the USA which legal existence began in April 9, 2014.

Company Address

Erytech Pharma SA

Batiment Adenine 60 avenue Rocke
LYON     69008
P: +334.78744438
F: +334.78755629

Company Web Links